Oncology Vol 28 No 4_Suppl_1

Radiobiology studies suggest that soft tissue sarcoma (STS) is a radioresistant tumor. We reviewed our institutional outcomes of patients treated with stereotactic body radiation therapy for metastatic STS.

To investigate the efficacy and morbidity of limb-sparing surgery with intraoperative radiotherapy (IORT) for patients with primary, nonmetastatic extremity and limb-girdle soft tissue sarcoma (STS) at high risk for recurrence.

Among patients with the top 10 causes of cancer death, those with Medicaid or without insurance were more likely to present with advanced-stage disease. This group also experienced worse survival when controlling for demographic information, stage at diagnosis, and receipt of definitive treatment.

Cancer treatment studies are well represented in high-impact oncology as well as general medical journals. We sought to evaluate the distribution and characteristics of oncology studies by intervention (radiation, surgery, cytotoxic chemotherapy, or targeted/systemic agents) in six high-impact oncology and general medical journals.

To evaluate recurrence patterns and overall survival in patients treated with adjuvant radiation after surgical staging for stage II endometrial carcinoma. Secondary goals include identification of prognostic factors for recurrence.

We have been treating patients with positive pelvic nodes with extended-field intensity-modulated radiation therapy (IMRT) to address the PA region prophylactically with a concomitant boost to the involved nodes. The purpose of this study is to assess regional control rates and recurrence patterns with this technique.

Linear accelerator-based stereotactic radiosurgery (SRS) is an effective treatment for selected melanoma patients with brain metastases. Recently, BRAF inhibitors have shown efficacy in stage IV melanoma. We sought to determine the effectiveness of SRS in patients with melanoma who are also being treated with BRAF inhibitors.

Cancer survivors may experience myriad late effects, and the Institute of Medicine recommends that survivorship care plans be provided to all. This study explores the willingness of health care providers (HCPs) and survivors to utilize mobile devices (MDs) for this purpose.

Here, we present the 1- and 2-year survival outcomes from patients with stage IB2–IVB cervical cancer treated with triapine radiochemotherapy.

We describe a method for prospectively collecting real-time, longitudinal datasets evaluating central nervous system (CNS)-directed IGRT across a multinational pediatrics consortium.

Our experience leads us to suspect that hypofractionation, as used in the US, increases toxicity without improving efficacy.

In this study, we present our institutional data on the clinical outcomes of radiation therapy plus temozolomide for anaplastic gliomas.

The purpose of our study is to report our institutional outcomes in treatment of brainstem metastases with gamma knife stereotactic radiosurgery for comparison.

Temporal lobe radionecrosis is a potential complication of high-dose radiation therapy for skull base tumors. The risk of radionecrosis increases with absolute doses greater than 60 Gy, but little data are available regarding potential partial volume effects when higher-dose conventionally fractionated radiotherapy is employed.

Previous data from our institution suggest that imaging evidence of extracapsular extension, identified on pretreatment CT scans, independently predicts for worse distant control and survival for oropharyngeal squamous cell cancer (OPC) patients undergoing radiation therapy. In this present study, we sought to validate these findings in non-OPC head and neck squamous cell cancers.

Our objective was to analyze the incidence of second primary cancer limited to the head and neck in a population with primary squamous cell carcinoma of the head and neck and its temporal trends in the human papillomavirus (HPV) era.

The purpose of this study is to report the long-term progression-free survival (PFS), overall survival (OS), and late-toxicity outcomes in pediatric patients with craniopharyngioma who have been treated with IMRT.

Low-grade gliomas (LGGs) are slow-growing, primary brain tumors that frequently recur after primary surgical treatment. Recent work has established the activation of the PI3K/mTOR pathway in most LGGs, raising the possibility that mTOR inhibitors, such as everolimus (RAD001), may benefit patients with LGG. Early imaging markers of treatment response and disease progression are needed to assess patients undergoing investigational therapy.

The purpose of our study is to evaluate the outcomes of patients treated with SBRT in the postoperative setting.

Single-fraction palliative radiotherapy for bone metastasis appears to be much more available for cancer patients receiving end-of-life care within the United Veterans Healthcare Administration when compared with the general US health care system.

The goal of this study is to compare survival, local control, and toxicity outcomes for non–small-cell lung cancer patients treated with SBRT for centrally versus peripherally located tumors.

Neoadjuvant chemoradiation is a standard treatment of locally advanced esophageal cancer. Preventive strategies to minimize postoperative morbidity will be important to help improve the clinical outcomes of patients. We investigated the factors associated with an increased incidence of anastomotic leaks among patients treated with neoadjuvant chemoradiation.

In this retrospective study, we sought to investigate the dose prescription pattern use in the US for patients receiving SBRT.

We evaluated the correlation between patient survival and reduction in gross tumor volume (GTV) using weekly cone-beam computed tomography (CBCT) to assess whether this could be prognostic of survival. We hypothesized that a greater percent decline in primary lung tumor volume during the course of treatment would correlate to improved patient survival.

The goal of this study was to optimize combination therapy with PARP1 inhibition and radiation for clinical assessment by establishing the most effective drug/radiation treatment schedule, determining the degree of PARP1-mediated radiosensitization across a range of drug doses, and identifying early biomarkers predictive of long-term treatment efficacy in preclinical BCa models.

There is conflicting evidence regarding the benefit of postmastectomy radiation therapy (PMRT) for pathologic stage T3N0M0 breast cancers. We performed a Surveillance, Epidemiology, and End Results (SEER) analysis to investigate the benefit of PMRT in these patients.

Purpose: Rhabdomyosarcoma of the perineal and perianal region (PRMS) has poor outcomes. We analyzed prognostic factors and patterns of failure, with an emphasis on radiotherapy for locoregional control.

To compare rates of pathologic response, downstaging, local control, and treatment-related toxicity in patients treated in a prospective phase II trial of preoperative short-course radiotherapy and sequential FOLFOX (folinic acid, fluorouracil, oxaliplatin) chemotherapy with patients treated at our institution with preoperative long-course chemoradiotherapy and adjuvant chemotherapy.

Although adverse sequelae of chemoradiation (CRT) for head and neck cancer (HNC) have been extensively detailed in recent years, the effects of CRT on voice and speech quality remain poorly characterized. We investigated changes in patient-reported voice and speech quality (VSQ) after CRT in two prospective studies of organ-sparing CRT for locally advanced oropharyngeal cancer (OPC).

To characterize the utilization of postprostatectomy radiation for patients with prostate cancer (CaP) at a National Cancer Institute (NCI)-designated Comprehensive Cancer Center over the past decade, given the introduction of robotic prostatectomy and the publication of multiple phase III trials showing a benefit for adjuvant postprostatectomy radiation.